June 20, 2022
Scott Schliebner joins TFS HealthScience to further grow the company offering.
Scott Schliebner has recently joined TFS as Senior Vice President, Clinical Development Services. Based in the US, Scott brings more than 25 years of clinical drug development expertise to TFS, having worked across the biotech, non-profit, small CRO, and large global CRO sectors. Scott will head up the Pediatric, Rare and Orphan Disease Business Unit and will provide additional leadership and growth for the CDS offering, particularly within the US.
Scott joins TFS following a decade at PRA Health Sciences (now ICON) where he developed and led several Centers of Excellence, including: Rare Diseases, Pediatrics, Vaccines, Gene Therapy, and Federally-Funded Research. Scott brings an entrepreneurial mindset to TFS, coupled with an emphasis on patient-focused approaches to drug development, utilization of data and technology to accelerate clinical trials, and a focus on innovation to bring new therapies to patients faster. Scott also serves on the Board of Directors for two rare disease-focused non-profit organizations – Uplifting Athletes and Angel Aid – and he serves as a Strategic Advisor for Jeeva Bioinformatics, Halo Health Systems, and Atomic Medical Innovations. Scott holds a masters in public health (MPH) degree from the University of Utah School of Medicine.